BioLawGics

BioLawGics Archives

Archives by Date

• 2011
  • Mar
  • Apr
  • May
  • Jun
  • Jul
  • Sep
• 2012
  • Feb
  • Mar
  • Apr
  • May
  • Jun
  • Jul
  • Sep
  • Nov
  • Dec

Archives by Category

• Antitrust
• Biosimilars
• FDA Approval
• Patent Law

Archives by Tag

• 262(k) Teva Neutroval Amgen filgrastim GCSF
,
• ACA
,
• Amgen
,
• Amgen Teva filgrastim
,
• Biologics biosimilar sales
,
• Biomarkers "diagnostic tests" DNA
,
• Biosimilar
,
• BPCIA
,
• CDER biomarker pharmacogenetics
,
• EMA
,
• EMA cluster
,
• Fabrazyme Genzyme Shelbyzyme non-enablement
,
• FDA Guidance
,
• figrastim
,
• FTC Report
,
• Genentech HGS
,
• Genetic Engineering and Biotechnology News
,
• GlaxoSmithKline
,
• GPhA
,
• Guidance
,
• Hatch-Waxman
,
• Hospira BLA
,
• India Guidelines
,
• Mayo v. Prometheus isolated DNA
,
• Myriad Prometheus
,
• Noerr-Pennington
,
• Nuepogen
,
• Off-label promotion
,
• Phrma Bio
,
• Section 101
,
• Supreme Court
,
• Teva
,
• utility
,
• Venture Capital